2024 Mease p et al. rheumatol ther. 2019 6:435

Mease p et al. rheumatol ther. 2019 6:435–450

Author: ojln

August undefined, 2024

WebMay 14, 2024 · Current treatment options for PsA include non-biologic disease-modifying antirheumatic drugs (DMARDs; i.e. methotrexate, sulfasalazine, ciclosporin and … WebMwangi James Murage,4 Jeffrey D Greenberg,6 William N Malatestinic4 To cite: Mease PJ, etzel cJ, Huster WJ, et al. Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the corrona registry. RMD Open 2024;5:e000867. doi:10.1136/ rmdopen-2024-000867 measures.

Understanding the association between skin …

WebJul 6, 2024 · Spondyloarthritis (SpA) comprises a group of rheumatic diseases that include ankylosing spondylosis (AS), reactive arthritis, psoriatic arthritis (PsA), juvenile SpA, and arthritis and spondylitis associated with inflammatory bowel disease, such as ulcerative colitis and Crohn disease ( 1 ). WebJan 10, 2024 · Background There are limited real-world data on the diagnostic experiences of patients with psoriatic arthritis (PsA), including medical care sought and potential barriers to diagnosis. We aim to describe patient experiences related to receiving a PsA diagnosis. Methods Ours was a mixed-method, 2-phase study. Phase 1 comprised concept … ra drugs law

A head-to-head comparison of the efficacy and safety of …

WebMease P, Deodhar A, Calheiros R, Meng X, Fox T, Baraliakos X. Impact of Peripheral Swollen and Tender Joints at Baseline on Response to Treatment with Secukinumab in Ankylosing … WebAug 1, 2024 · The Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA) RCT 19 reported that both ETN … WebJun 29, 2024 · At week 16, patients in any treatment group with less than a 5% improvement in both the tender and swollen joint counts could start or increase the dose of non-steroidal anti-inflammatory drugs, oral corticosteroids, or non-biologic disease-modifying anti-rheumatic drugs (consistent with doses allowed in the inclusion criteria). dramatist\u0027s 7g

Comparative effectiveness of guselkumab in psoriatic arthritis: results f…

Sustained Very Low Disease Activity and Remission in …

WebNov 14, 2024 · Introduction. Psoriatic arthritis (PsA) is a chronic, inflammatory disease characterized by peripheral arthritis, axial disease, dactylitis, enthesitis, and skin and nail psoriasis 1, 2.PsA can negatively affect patients’ daily functioning and quality of life as a result of permanent joint damage and disability 3.The reported prevalence of PsA in the … WebFeb 1, 2024 · Secukinumab resulted in early, statistically significant, clinically meaningful, sustained improvements in PROs across all doses compared with placebo in patients with active psoriatic arthritis. These improvements were seen irrespective of previous TNF inhibitor use, in a post-hoc analysis. These results indicate that secukinumab provides … dramatist\u0027s 7nWebThe primary objective was to evaluate whether IXE was superior to ADA at week 24 for simultaneous achievement of a ≥50% improvement from baseline in the American College … radrugs

"" - Mease p et al. rheumatol ther. 2019 6:435–450

Mease p et al. rheumatol ther. 2019 6:435–450

Comparative effectiveness of guselkumab in psoriatic arthritis

WebNational Center for Biotechnology Information WebAug 19, 2024 · Sustained remission was defined when patients achieved a DAPSA score ≤ 4 and/or VLDA for at least 12 months. The exclusion criterion was the presence of a …

Did you know?

WebDec 5, 2024 · SPIRIT-P2 is a phase 3, randomized, double-blind, PBO-controlled clinical study that comprised two treatment periods: the double-blind (weeks 0–24) and extension (weeks 24–156) periods. The methods have been reported in detail previously [in brief, see the electronic supplementary material (ESM) file] [ 15, 18 ]. WebAug 11, 2024 · Aliment Pharmacol Ther. 2024;50(10):1068-76. Mease P et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. ... Arthritis Rheumatol. 2024;71(7):1042-55. Cohen SB et al. Long-term safety of tofacitinib …

WebMar 11, 2024 · Rheumatology key messages A number of single-domain and composite outcome measures are utilized in PsA clinical trials. The variety of assessments reflects the multifaceted nature of PsA and can answer different questions. Future digitalization of outcomes may change assessment of disease activity and patient impact in PsA. … WebMease P et al. rMD Open 20245:e000880 doi:101136/rmdopen-2024-000880 1 Original article Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry

WebMease P et al. rMD Open 20245:e000880 doi:101136/rmdopen-2024-000880 1 Original article Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) … WebPhilip Mease MD, MACR Seattle Rheumatology Associates (Swedish Orthopedic Institute) – Providence Connect Director, Rheumatology Research, Swedish Medical Center/ Providence St. Joseph Health Clinical Professor, University of Washington School of Medicine 26thAnnual Pain Management Symposium 10/7/2024 2 P Mease Disclosures

WebNov 17, 2024 · Mease P, Coates LC, Helliwell PS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): …

WebNov 25, 2024 · Presented at the 2024 EULAR E-Congress June 3-6. Mease, P, et al. Efficacy of Guselkumab, a Monoclonal Antibody that Specifically Binds to the p19 Subunit of IL-23, on Axial-Related Endpoints in Patients with Active PsA with Imaging-Confirmed Sacroiliitis: Week-52 Results from Two Phase 3, Randomized, Double-blind, Placebo-controlled … dramatist\u0027s 7hWebSep 14, 2024 · The search informing Mease et al. 2024 was updated in February 2024. A subsequent hand-search was performed to identify newer agents, including abstracts, up to July 2024. There were no date restrictions on the search strategy or results. Study selection, data extraction and quality assessment dramatist\u0027s 7rWebMease, et al: MDA with adalimumab 647 Personal non-commercial use only. The Journal of Rheumatology Copyright © 2013. All rights reserved. Application and Modifications of … dramatist\u0027s 7mWebMethods Patients with active PsA were randomised (1:1) to approved dosing of IXE or ADA in an open-label, head-to-head, blinded assessor clinical trial. The primary objective was to evaluate whether IXE was superior to ADA at week 24 for simultaneous achievement of a ≥50% improvement from baseline in the American College of Rheumatology criteria … dramatist\u0027s 7uWebJun 17, 2024 · The comparison of the coefficients using the 95% confidence interval showed that MASES had a better correlation with BASDAI compared to LEI (p = 0.018).There was no statistical difference between MASES and SPARCC (p = 0.212) or between SPARCC and LEI (p = 0.14).In the analysis of ROC curves, the three enthesitis scores could discriminate … dramatist\u0027s 7sWebGladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2): ii14 – ii17. , [Web of Science ®], [Google Scholar] Merola JF, Herrera V, Palmer JB. Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA. Clin Rheumatol. rad rugsWebCorrection to Lancet Rheumatol 2024; 1: e145–53. Full-Text HTML; PDF News. e688. e688. Research in Brief. Jennifer Thorley; Full-Text HTML; PDF e689. e689. FDA approval for … dramatist\u0027s 7t